ONCOSEC MEDICAL steigt auf über 2 Dollar

After Hours: $ 0,475 0,0239 (+5.30%)  

http://www.wallstreet-online.de/nachricht/...agg-pink-nsrgy-pink-pwei  

OncoSec Medical, Inc. (ONCS.OB) appears to be one of the best-kept secrets in the biotech sector.  

http://finance.yahoo.com/q/...0,m200&a=m26-12-9,r14,ss,p12&c=  

Support & Resistance More
2nd Resistance Point   0.5170  
1st Resistance Point 0.4841  

mehr geht nicht

http://www2.barchart.com/opinions/stocks/ONCS  

http://www.boerse-berlin.de/index.php/Aktien?isin=US68234L1089  

http://www.pennystocks.de/lig/  

ab sofort ist der Handel in Berlin möglich




http://www.boerse-berlin.de/index.php/Aktien?isin=US68234L1089  

http://www2.barchart.com/quotes/stocks/ONCS  

http://oncosec.com/index.php/corporate-governance/analyst-coverage/

Rahul Jasuga auf über 5 Dollar ?  

http://www.nasdaq.com/symbol/oncs/after-hours  

http://app.quotemedia.com/quotetools/...;cp=off&webmasterId=89753  

http://www.nasdaq.com/symbol/oncs/premarket  

http://ih.advfn.com/...chart&s=NB^ONCS&p=0&t=19&vol=1  

http://www.otcmarkets.com/stock/ONCS/quote  

Eine wichtiger Meilenstein für Oncosec:

OncoSec, UCSF, and Merck Initiate a Landmark Phase IIb Combination Trial of Breakthrough Drug KEYTRUDA® And ImmunoPulse to Treat Metastatic Melanoma

http://punitdhillon.com/2014/11/25/...e-to-treat-metastatic-melanoma/

 

bin gespannt wie die amis reagieren
http://www.businesswire.com/news/home/...ration-Evaluate#.VORzUC7adGE  

PR NEWSWIRE 1:09 PM ET 5/27/2015 


SAN DIEGO , May 27, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") , a company developing DNA-based intratumoral cancer immunotherapies, today announced the company has received approval to begin trading its common stock on The NASDAQ Stock Market LLC. OncoSec's common stock will begin trading on The NASDAQ Stock Market LLC at the opening of market hours on Friday, May 29. 

"Over the past year, our team has made significant headway to build a strong, cutting-edge, clinical stage biotech company. As we become a NASDAQ-listed company, we are now able to communicate our progress with a broader audience, raise the visibility of OncoSec's capabilities, and generate more value for our shareholders," said Punit Dhillon, President and CEO of OncoSec. "We are now in a better position to continue to advance our intratumoral immunotherapy technologies with the goal of one day benefiting cancer patients everywhere." 

 

OncoSec Medical Announces FINRA Approval of Reverse Stock Split

Print

Alert

OncoSec Medical Incorporated (USOTC:ONCSD)
Historical Stock Chart

1 Month : From Apr 2015 to May 2015

SAN DIEGO, May 15, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Financial Industry Regulatory Authority ("FINRA") has approved the company's 1-for-20 reverse stock split. According to FINRA's approval, the reverse stock split will become effective and OncoSec's common stock will begin trading on a post-split basis before the open of trading on May 18, 2015.

 

https://www.analystratings.com/articles/...g-on-oncosec-medical-oncs/